NEW YORK, Dec. 15, 2017 /PRNewswire/ -- In keeping with the commitment to dynamically provide members with timely information,WallStEquities.com has issued free tailored Stock Review on HZNP, AKTX, MYOS, and ZYNE which is a click away at www.wallstequities.com/registration. WallStEquities.com concentrates on the Generic Drugs market, which can be segmented into biosimilars,
Shares in Dublin, Ireland headquartered Horizon Pharma PLC saw a drop of 1.53%, ending Thursday's trading session at $14.84. The stock recorded a trading volume of 1.25 million shares. The Company's shares have gained 13.54% in the last one month and 22.54% over the last three months. The stock is trading 6.84% and 12.54% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Horizon Pharma, which engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the US and internationally, have a Relative Strength Index (RSI) of 60.95.
On November 30th, 2017, Horizon Pharma named Shao-Lee Lin, M.D., Ph.D. as Executive Vice President – R&D and Chief Scientific Officer. He will be reporting directly to Timothy P. Walbert, Chairman, President, and CEO. Dr. Lin will join the Company in early January 2018. Complimentary subscription to our free research report on HZNP at: www.wallstequities.com/registration/?symbol=HZNP
New York-based Akari Therapeutics PLC's stock dropped 3.05%, closing the day at $4.13 with a total trading volume of 511,097 shares. The stock is trading 15.14% below their 50-day moving average. Shares of the Company, which focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases, have an RSI of 34.62.
On December 08th, 2017, Akari Therapeutics announced that the three, additional patients that were enrolled into the Phase-II COBALT trial of CoversinTM in paroxysmal nocturnal hemoglobinuria, considered together with the earlier five patients, met the primary endpoint. The primary endpoint in this clinical trial is reduction in serum lactate dehydrogenase, an indication of hemolysis, to ?1.8 times the upper limit of normal for the investigator's reference laboratory to day 28. Access the free research report on AKTX now by signing up at: www.wallstequities.com/registration/?symbol=AKTX
MYOS RENS Technology
On Thursday, shares in Cedar Knolls, New Jersey-based MYOS RENS Technology Inc. recorded a trading volume of 11,028 shares. The stock ended the day 0.82% lower at $1.31. The Company's shares have advanced 11.02% on an YTD basis, and are trading below their 50-day moving average by 2.40%. Furthermore, shares of the Company, which focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue, have an RSI of 46.16.
On December 06th, 2017, MYOS RENS Technology (MYOS) has entered into a research agreement with the University of California, Berkeley's Department of Nutritional Sciences & Toxicology. The study will look into the effects of Fortetropin® on increasing the fractional rate of skeletal muscle protein synthesis in men and women between 60 and 75 years old. Are you already registered with Wall St. Equities? Do so now for free, and get the report on MYOS at: www.wallstequities.com/registration/?symbol=MYOS
Devon, Pennsylvania headquartered Zynerba Pharmaceuticals Inc.'s stock dropped 2.56%, finishing yesterday's session at $11.42 with a total trading volume of 232,486 shares. The Company's shares have surged 83.31% in the previous three months. The stock is trading above its 50-day moving average by 0.17%. Additionally, shares of Zynerba Pharma, which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery, have an RSI of 43.84.
On December 03rd, 2017, Zynerba Pharma announced that Terence O'Brien, MD of the Royal Melbourne Hospital at The University of Melbourne presented new data from the completed Phase-2 STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) study and ongoing STAR 2 18-month open label extension study evaluating ZYN002 cannabidiol transdermal gel in patients with focal seizures. Key findings included that clinically meaningful responses to ZYN002, as measured by reductions in focal seizures from the baseline period of STAR 1, are correlated with continued treatment with ZYN002. Aspiring Member, please take a moment to register below for your free research report on ZYNE at: www.wallstequities.com/registration/?symbol=ZYNE
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/technical-perspectives-on-horizon-pharma-akari-therapeutics-myos-rens-technology-and-zynerba-pharma-300571921.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Black food is the new green owing to its health benefits from cardiovascular health to weight loss. ...
Scurvy is a condition that occurs due to the deficiency of vitamin C. It occurs only rarely, since ...
Pets can give you diseases. Surprised? You may love your pet but beware! Your pets might be ...View All